NCT02836158View on ClinicalTrials.gov

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2030

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

R-IDARAM plus intrathecal chemotherapy

R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.

Trial Locations (1)

100048

RECRUITING

Navy General Hospital, Beijing

All Listed Sponsors
lead

Navy General Hospital, Beijing

OTHER

NCT02836158 - Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | Biotech Hunter | Biotech Hunter